Colorado, USA-primarily based Folium Biosciences mentioned it has purchased FeyeCon, a designer of substantial scale supercritical CO2 extraction technologies primarily based in Weesp, Holland.
Folium mentioned the move offers the organization “an added level of vertical integration,” and strengthens its capacity to manage the production approach from seed to sale.
The firms did not announce the monetary particulars of the deal.
“We have acquired vested pharmaceutical R&D licenses as effectively as Active Ingredient licenses, and a extensive IP portfolio that contains more than 150 patents,” Folium CEO Kashif Shan mentioned of the acquisition, which he noted will “speed along our pharmaceutical division and Rx joint ventures in the active ingredient and new item improvement space.”
Woerlee transitions to CTO
FeyeCon’s CEO, Geert Woerlee, an business veteran who holds many patents and trade secrets relevant to extraction technologies, will turn into Folium Biosciences’ CTO.
FeyeCon installed extraction and purification gear at Folium Biosciences’ 110K sq. ft. facility in Colorado. 5 SFE CO2 extraction skids with an 800K lb. biomass month-to-month capacity will be deployed this spring, along with other state-of-the-art gear, the organization mentioned.
Plans for Canada, S. America
Folium Biosciences mentioned it has extra than 300,000 sq. ft. of manufacturing space in southern Colorado for processing, extraction and purification operations, with building underway on a 170,000 sq. ft. facility in Canada that will mirror existing operations in Colorado. South American facilities are in the organizing stages, the organization mentioned.
Folium also announced that M. Vanessa Fernandez will join the organization as VP of Item Improvement and High-quality. She has a background in R&D, and has consulted on pharmaceutical developments for many European and American firms.